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Abstract 
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer with 
an estimated over half million people diagnosed annually. Due to the difficulty in early 
diagnosis and lack of effective treatment options, the 5-year survival rate of HCC 
remains between 6 and 11%. The identification of better diagnostic and prognostic 
biomarkers, along with new therapeutic agents is of paramount importance. Long non-
coding RNAs (lncRNAs) are abundantly transcribed, participating in nearly every single 
step of genomic regulation ranging from transcription, post-transcription to chromatin 
modification. While lncRNAs such as XIST and H19 were discovered in early 90’s, the 
investigation of lncRNAs at a functional level has remained a fledgling area until 
recently. Currently, it is estimated that over 30000 lncRNAs are detectable across the 
human genome. Furthermore, a well organised intrinsic network between lncRNAs and 
other ncRNAs such as microRNAs has been suggested. Dysregulation  of lncRNAs has 
been found in a range of cancers including HCC. Well-characterised lncRNAs have 
been shown to be specifically expressed in HCC and suggested as an independent risk 
factor for poor prognosis. Moreover, it was discovered that the regulation of lncRNAs 
increased the sensitivity of HCC patients to chemo-therapy. This review focuses on the 
recent findings of lncRNAs in HCC development and progression, with particular 
attention on epigenetic regulation, as a central molecular mechanism in 
hepatocarcinogenesis. In addition, in silico analysis was conducted to demonstrate 
potential intrinsic linkage between lncRNAs and microRNAs in HCC pathogenesis. 
While lncRNAs were previously considered as “background noise” in human genomics, 
their investigation may represent a new milestone in the understanding of HCC 
providing highly sought after novel diagnostic and therapeutic management approaches 
for this lethal condition. 
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1. Introduction     
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer with 
an estimated over half million people diagnosed annually [1]. While extensive efforts 
have been carried out in both research and clinical management, mortality rates remain 
the third highest for neoplastic death in the world. This is mainly due to difficulty in early 
diagnosis and lack of effective treatment options. Patients that present at clinics with 
HCC are usually at an advanced stage of their disease. This results in limited suitability 
for liver resection and transplantation. Therefore identifying new diagnostic and 
prognostic biomarkers, along with therapeutic agents for HCC is of paramount 
importance.  
With the development of new biological technologies such as deep sequencing and 
DNA tiling arrays, biomedical scientists are able to investigate gene expression in great 
detail unravelling the pathogenesis of human diseases. Subsets of the transcriptome 
that are actively transcribed, however lack protein coding ability are collectively termed 
as non-coding RNAs [2]. MicroRNAs are a group of evolutionarily conserved non-coding 
RNAs (19-24 nucleotides) that regulate target genes at a post-transcriptional level, 
competitively binding to the 3’ untranslated regions (3’UTRs) of messenger RNAs 
(mRNAs). This biological process leads to either the inhibition of mRNA translation or 
the destruction of mRNA [3]. In fact, microRNAs are now considered to be key players 
essential in cellular processes such as proliferation, embryogenesis, and apoptosis. 
They are also robust biomarkers in cancer research with a utility in diagnostics, 
prognostics and therapeutic intervention. The role of microRNAs as diagnostic, 
prognostic and therapeutic agents in HCC has been reviewed elsewhere [4]. Long non-
coding RNAs (LncRNAs) offer many of the same properties with respect to being stable 
biomarkers, capable of withstanding multiple freeze thaw cycles and regulating multiple 
genes; nonetheless, compared to microRNAs the study of lncRNAs is in its infancy.  
 
2. Long non-coding RNAs  
While lncRNAs such as XIST and H19 were discovered in early 1990, detailed 
investigations of their expression and function have only recently emerged [5,6]. Due to 
their similarity to other non-coding RNAs, no distinct definition can specifically include all 
biochemical features that are associated with lncRNAs. In order to distinguish lncRNAs 
from other ncRNAs, lncRNAs are commonly separated from small ncRNAs such as 
microRNAs at a cut-off point of 200 nucleotides in length. Most lncRNAs are transcribed 
by RNA polymerase II followed by general RNA processes including 5’ terminal 
methylguanosine capping, splicing and 3’ end polyadenylatation[7,8]. It has been 
suggested that over 30000 lncRNAs can be detected across the human genome 
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(Arraystar Human LncRNA Array v3.0) [9]. While previously considered “background 
noise” within the transcriptome, recently an in silico computational analysis revealed 
that lncRNAs are actively involved in cell differentiation, immune cell activation and 
differentiation [10]. In addition, mounting evidence has demonstrated that they are 
pivotal gene regulators at various levels, and their dysregulation is closely related to 
human diseases including cancer [11,12]. For example dysregulation of the lncRNAs 
BCAR4, PCA3 and HULC are associated with breast cancer, prostate adenoma and 
HCC, respectively [13-15]. Whether or not the dysregulation of lncRNAs is the causative 
factor or merely a symptomatic consequence remains to be clarified.  
LncRNAs are diversely expressed across various genes. They regulate their target 
genes at the transcriptional, post-transcriptional and translational levels [7]. Based on 
their expression location within a gene, lncRNAs can be further divided into 
sense/antisense (same/complementary sequence on the same or opposite strand of a 
transcript), bidirectional (located at the opposite strand near the transcription initiation 
site of a transcript), intronic (embedded totally within an intron of a transcript) and 
intergenic lncRNAs (located between the genomic interval of two transcripts) [16,17]. In 
recent years, increased attention has revealed that the biological functions of lncRNAs 
range from X chromosome activation and genomic imprinting (Xist and H19, 
respectively) to gene regulation, cell cycle regulation, protein scaffolding and chromatin 
modification. Nevertheless, further research is still required in order to fully elucidate 
their functions.  
LncRNAs can act as an antisense strand with complementary sequences to their target 
genes. This results in their target gene inhibition or reduction in activity (Figure 1). For 
example, lncRNA HULC may downregulate microRNA372 and the tumour suppressor 
gene p18 leading to the promotion of HCC cell proliferation [18,19]. LncRNAs can also 
act as a protein scaffold either recruiting histone modification proteins to influence 
expression of their target genes or competitively binding to essential proteins initiating 
conformational change that can activate or inhibit expression of target genes. Recently, 
a study using photoactivatable-ribonucleoside-enhanced crosslinking and immune-
precipitation (PAR-CLIP) revealed that lncRNAs interact with microRNAs, suggesting an 
intrinsic crosstalk exists between ncRNAs in the development and progression of 
cancer [20]. In fact, accumulating evidence has demonstrated dysregulation of 
microRNAs by lncRNAs and vice versa in hepatocarcinogenesis [18,21,22].  
While lncRNAs are often less conserved across species, their tissue and cell specificity 
make them excellent potential candidates in cancer diagnosis and prognosis. Recent 
evidence indicated that lncRNAs may be used as potential prognostic biomarkers 
associated with therapeutic response in cancers [23-25]. In this context, there is no 
doubt that the importance of lncRNAs will revolutionise the traditional concepts of the 
transcriptome and the pathogenesis of liver cancer. 
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3. LncRNAs and HCC 
While there is an increasing interest in lncRNAs, to date only a handful has been 
investigated in HCC.  Herein we review the current knowledge regarding lncRNAs in the 
development and progression of HCC.  
 
Highly up-regulated in liver cancer (HULC) 
HULC was the first hepatocyte specific lncRNA identified in 2007 [26]. The expression of 
HULC is upregulated 33-fold in human HCC tissue compared to normal liver tissues, 
whereas the level of HULC in other tumorigenic tissues such as lung, colon and 
prostate is very low in comparison. Interestingly, HULC is only slightly upregulated in 
cirrhotic liver tissue, suggesting its specificity in hepatocarcinogenesis. In fact, HULC is 
reported to be elevated not only in HCC, but also during intrahepatic metastasis [27].  
Hepatitis B (HBV) and hepatitis C (HCV) still remain the predominant etiological factors 
in the onset and development of HCC. However, the molecular processes involved in 
the conversion of an infectious liver disease to cancer remains to be fully elucidated. 
The HBV X protein (HBx) has been reported to elevate HULC expression in HBV 
patients with or without the presence of a liver tumour (Table 1). This is consistent with 
in vitro studies whereby HBx was shown to increase HULC expression levels both in 
normal liver cells (L-O2) and liver cancer cells (HepG2) (Table 2). These data point 
towards an important role for HBx in the onset and development of HCC [19]. The 
mechanism involves HULC-mediated  downregulation of p18 (a regulator of cell cycle 
and tumour suppressor gene p53) giving rise to increased proliferation of HCC cells. 
Overexpression of HBx was shown to increase the activity of the HULC promoter region, 
which is critical for transcription initiation. It has been demonstrated that a cyclic-AMP 
responsive element binding protein (CREB) binding site is located at the core promoter 
of the HULC gene and its inhibition can dramatically reduce promoter activity, thus 
influencing transcription initiation [18]. Mounting evidence has illustrated that a close 
relationship exists between CREB and HBV in the pathogenesis of HBV-HCC [28,29]. 
Therefore, HBx may induce the expression of HULC via CREB.  
Cumulative evidence has pointed towards a closely related interaction between 
lncRNAs and microRNAs [20]. It has been illustrated that HULC has a conserved 
binding site for microRNA372, thus suggesting that it can mediate an antisense effect 
on microRNA372 (miR-372). Such an event could dramatically influence the activity of 
miR-372 and its target genes, for example cAMP-dependent protein kinase catalytic 
subunit beta (PRKACB). Once activated by protein kinase A (PKA), PRKACB 
translocates to the nucleus further activating CREB by phosphorylation [18]. Co-
incidentally, phosphorylated CREB is significantly elevated in a rat model of HCC [30]. 
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Importantly,  in liver cancer cells the HULC promoter is more sensitive to histone 
modification than normal hepatocytes; this may in turn result in the aberrant expression 
of HULC and its target genes including miR-372. Recently, HULC was shown to be 
destabilised by a specific member of IGF2 mRNA-binding proteins; this study may 
provide a novel insight for the targeting of HULC in HCC therapeutics [31]. 
Hox transcript antisense intergenic RNA (HOTAIR) 
HOTAIR is a lncRNA located on chromosome 12q13.13. HOTAIR has been particularly 
studied as an oncogene involved in the promotion of metastasis by means of chromatin 
modification events and is also a promising biomarker that can indicate poor prognosis 
in breast cancer and colorectal carcinoma [32,23].  Notably, a higher expression level of 
HOTAIR has been strongly correlated with liver metastasis in colorectal cancer patients. 
Multivariate analysis estimates that colorectal carcinoma patients with a high HOTAIR 
expression level have an increased relative risk in overall survival (RR = 5.62, p = 
0.008). In fact, it has been recently demonstrated that HOTAIR expression in HCC 
tumours was significantly higher than in the adjacent non-tumour tissues, especially in 
HCC patients with lymph node metastasis (Table 1) [33,34]. The mechanistic role of 
HOTAIR in HCC remains to be unravelled. However, it has been shown that HOTAIR 
may positively regulate the expression levels of multiple metastatic genes including 
vascular endothelial growth factor (VEGF) and matrix metallopeptidase 9 (MMP9). This 
may partly explain its high expression in HCC patients with lymph node metastasis and 
its essential role in tumour migration and invasion (Table 2).  
HOTAIR is a well-known protein scaffolding lncRNA binding to the polycomb repressive 
complex 2 (PRC2) and lysine-specific demethylase 1 (LSD1) via its 5’ and 3’ regions 
respectively. This can also result in the recruitment of enzymes involved in histone 
modification, leading to the repression of essential tumour suppressor genes [12]. It was 
found that the inhibition of HOTAIR in liver cancer cells (BEL7402 and HepG2) can 
significantly reduce cell proliferation and sensitise cells to treatment with standard 
chemotherapy drugs such as Cisplatin and Doxorubicin in a dose dependent manner 
(Table 2). Moreover, HOTAIR has also been reported as an independent biomarker for 
HCC recurrence-free survival after liver resection or transplantation, a finding that is 
consistent with other studies on breast and colorectal cancer (Table 3). In view of these 
findings, HOTAIR is likely to represent and important functional and prognostic factor in 
liver cancer. 
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H19 
The H19 gene is located in chromosome 11p15.5 that encodes a lncRNA that has a 
pivotal role in human embryogenesis. H19 was identified as having a role in cancer 
tumour suppression using embronal tumours [35]. It has been reported that the 
expression level of H19 is normally at a low level during adulthood. However, it has 
been shown to be aberrantly up-regulated in liver cancer, particularly HBV-induced HCC  
[36]. The mechanism underlying this aberrant expression was demonstrated to be due 
to a gain of function (a process of converting the silenced copy of the gene to an 
actively expressed gene). This can lead to a shift from monoallelic expression to biallelic 
expression leading to  the upregulation of H19 in HCC. This imbalance between H19 
and its closely related paternally imprinted gene, insulin-like growth factor 2 (IGF2) was 
proposed to have a role in HCC development and progression in late 90’s [37]. In vitro 
the expression of H19 has been shown to be elevated in several liver cancer cell lines 
under various conditions, especially hypoxia [38]. Moreover, H19 knockout CD-1 nude 
mice subcutaneously implanted with Hep3B liver cancer cells have an 82% reduction in 
both mean tumour volume and weight, revealing the essential role that H19 plays in 
HCC tumour development (Table 2). However, a recent study reported that H19 was 
generally elevated in non-tumour tissue of less than 2 centimetres apart from the HCC 
tumour tissue site compared with the intratumoral section [22]. Furthermore, a low ratio 
of H19 expression in intratumoral tissue versus non-tumour tissue was associated with 
invasiveness and decreased disease-free survival (Table 3). Taken together, these data 
point towards roles for H19 in HCC development and metastasis. While the mechanism 
by which H19 contributes to the pathogenesis of HCC is still unclear, the results from 
several recent studies certainly suggest that H19 is important in HCC onset and 
progression. Many lncRNA genes are located in the same chromosome cluster with 
other important cancer related genes. The cell cycle inhibitor P57Kip2 is located in the 
same cluster as H19 and was demonstrated to be downregulated in HCC tissue 
compared with normal liver tissue. This suggests that H19 may promote HCC via 
directly disrupting specific cell cycle processes [38]. Moreover, H19 can be aberrantly 
regulated by the oncogene, c-Myc, through either histone acetylation or hyper/hypo-
methylation in differentially methylated regions (DMR) during hepatocarcinogenesis. 
These data clearly illustrate a pivotal mechanistic role for epigenetics.     
 
Maternally expressed gene 3 (MEG3) 
The MEG3 gene is located at the DLK1-MEG3 locus of chromosome 14q32.3. MEG3 
functions as a tumour suppressor gene and a regulator of other well-known tumour 
suppressor genes including p53 and its target genes. A recent study observed that 
MEG3 was down-regulated in 81% of HCC human samples (Table 1) [21]. HCC cells 
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transfected with MEG3 had decreased anchorage-dependent growth, elevated retention 
between G0/G1 phases in the cell cycle process and induction of cell apoptosis (Table 
2). Thus MEG3 may interfere with the cell cycle process by directly upregulating cell 
cycle regulators including p21. The expression of MEG3 is often lost in many cancer 
tissues as a result of gene deletion, hypermethylation of its promoter or 
hypermethylation of DMR [39,40]. Concomitantly, the expression of MEG3 has been 
demonstrated to be increased in HCC cells (HepG2 and Huh7) treated with the 
methylation inhibitor (5-Aza-dc) and the inhibition of DNA methyltransferase (DNMT1 
and DNMT3B) (Table 2).  
High expression in HCC (HEIH) 
HEIH is a newly identified lncRNA suggested to be central in hepatocarcinogenesis. 
The expression of HEIH was recently shown to be significantly elevated in HCC patients, 
especially with liver cirrhosis (Table 1) [41]. In addition, HEIH was found to be highly 
associated with HCC recurrence and an independent prognostic factor in overall patient 
survival (Table 3). Concurrently, data from in vitro studies reveal that the basal 
expression of HEIH is higher in liver cancer cell lines (HepG2 and Huh7) and that 
targeting HEIH for inhibition reduces overall cell proliferation. Interestingly, the 
expression of HEIH in HCC has been demonstrated not to be affected by either histone 
acetylation or DNA methylation, indicating that not all lncRNAs are epigenetically 
regulated in tumorigenesis [41]. LncRNAs can act as an intermediate protein scaffold, 
recruiting functional enzymatic proteins. This may lead to the upregulation or 
downregulation of target genes. It has been shown that the interaction of HEIH with the 
enhancer of zeste homolog 2 (EZH2) (an essential subunit of PRC2 complex) was 
required to down-regulate central cell cycle regulators such as p21 in HCC. Importantly, 
EZH2 has been demonstrated to have an important role in liver cancer metastasis via 
the negative regulation of microRNAs that have a specific tumour suppressor function, 
such as microRNA139-5p, microRNA125b, microRNA101, let-7c and microRNA200b  
[42]. In order to investigate interactions between HEIH and other target genes, studies 
utilizing the cancer co-expression network revealed that HEIH expressions can be 
correlated to two lncRNAs and 16 protein-coding genes, some of which are still 
functionally uncharacterised. 
 
Down-regulated expression by HBx (Dreh) 
Over 400 lncRNAs are either up-regulated or down-regulated in HBx transgenic mice  
[43]. Notably, the lncRNA Dreh was significantly down-regulated in HBx-transgenic mice. 
In vitro studies have shown that liver cells transfected with HBx have lower levels of 
Dreh, resulting in the induction of cellular proliferation and invasion (Table 2) [43]. In 
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addition, mice injected with liver cells that express Dreh were observed to have a 
reduced tumour weight and significantly less metastasis. The human form of Dreh 
(hDreh) (located on chromosome 5) is markedly reduced in HCC patients; its down-
regulation is accompanied with decreased overall survival rate. On occasion lncRNAs 
may interact with proteins to induce conformational changes and deactivate their 
specific target proteins7. In this context it has been demonstrated that Dreh could act as 
a tumour suppressor gene through its interaction with the filament protein, vimentin. 
This interaction was noted to induce changes in the cytoskeleton structure of liver 
hepatoma cells. Vimentin is an essential metastatic marker that is often overexpressed 
in HCC metastasis [44]. 
Microvascular invasion in HCC (MVIH) 
MVIH is a newly identified lncRNA residing in the same chromosomal region as the 
ribosomal protein S24, yet independently transcribed [45]. The expression of MVIH is 
reported to be almost 4-fold elevated in HBV-HCC patients. It has been demonstrated 
that MVIH expression positively correlates with microvessel invasion, tumour growth 
and intrahepatic metastasis (Table 1 and 2). These data suggest that MVIH may 
represent an independent prognostic factor, with high levels predicting poorer 
recurrence-free survival and overall survival in post-operative HCC patients, and be 
useful in the surveillance of patients (Table 3) [45]. It was hypothesized that MVIH may 
promote angiogenesis by interacting with the anti-angiogenesis protein 
phosphoglycerate kinase 1 (PGK1) produced by tumour cells [46]. The concentration of 
PGK1 in conditioned medium from liver cancer cells (Huh7 and HCCLM3) transfected 
with MVIH was markedly reduced compared with negative controls [45]. Moreover, 
human umbilical vein endothelial cells (HUVECs) in conditioned medium from liver 
cancer cells showed an enhanced formation of capillary-like structures, indicating 
metastatic potential. Mice subcutaneously implanted with liver cancer cells that had 
been transfected with the MVIH gene had increased microvessel density within the 
tumour. Importantly, the upregulation of MVIH was reported to be inversely correlated 
with PGK1 levels in serum and positively associated with microvessel density in HCC 
patients. 
 
Low expression in tumour (LET) 
Recently, the lncRNA LET was reported to be decreased in HCC, colorectal cancers 
and squamous-cell lung carcinomas, indicating suppression may be associated with 
intra- or extra-hepatic metastasis [47]. In fact, the level of LET has been shown to be 
reduced in both HBV-HCC and HCC patients and its low expression correlates with 
tumour micro-metastasis and encapsulation (Table 1). Mice injected with liver cancer 
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cells overexpressing the LET gene exhibited diminished tumour cell growth, hepatic and 
abdominal metastasis (Table 2). Hypoxia is a pivotal characteristic associated with the 
tumour microenvironment. In this context, the level of LET is dramatically down-
regulated, leading to stabilisation of nuclear factor 90 (NF90) proteins and its target 
gene hypoxia induced factor (HIF-1α). LET has a 1:1 stoichiometry with NF90 in 
normoxic conditions and over-expression of LET can repress NF90. In fact, LET can 
dramatically reduce the stability of NF90 by up to 66% in liver cancer cells (Table 2). It 
was demonstrated that the down-regulation of LET under hypoxic conditions may be 
under the control of histone deacetylation. Decreased histone 3 (H3) and histone 4 (H4) 
were observed in the LET promoter region, but no other areas across LET gene. The 
elevation of histone deacetylase 3 (HDAC3) under hypoxia was demonstrated to 
increase the expression of HIF-1α through the downregulation of LET. Moreover, the 
suppression of LET was shown to be recovered with the HDAC inhibitor Trichostatin A 
(TSA) even under hypoxic conditions. 
 
Metastasis associated lung adenocarcinoma transcript 1 (MALAT1) 
MALAT1 is an lncRNA located on chromosome 11q13.1 that is widely expressed in 
many tissues [48]. Chromosomal translocation is a condition where regions within two 
chromosomes are broken and rearranged in a different way. This abnormality is often 
observed with the aberrant expression of MALAT1, and is associated with an increased 
genomic instability leading to its up-regulation in many cancers including HCC [49-51]. 
While MALAT1 was initially identified as a biomarker for poor prognosis in non-small cell 
lung cancer, a recent study reported supraphysiological levels of MALAT1 in HCC 
patients that have undergone liver transplantation that concurrently revealed a higher 
risk factor for tumour recurrence [52,53]. Inhibition of MALAT1 in a preclinical liver 
cancer cell line (HepG2) effectively reduced cell viability, motility, invasiveness and 
increased their sensitivity to apoptosis. 
Several more lncRNAs have been newly identified to have crucial roles in HCC. These 
include: 1) chemotherapy drug associated lncRNA, Adriamycin resistance associated 
(ARA) in HCC cell proliferation [54]. 2) Ultraconserved lncRNA (ucRNA), TUC339 acting 
as a messenger within hepatocarcinogenesis microenvironment [55]. 3) Potential 
biomarker of HCC disease progression and outcome, HOTTIP/HOXA13 [56]. 4) Histone 
deacetylase inhibitor (Trichostatin A) dependent lncRNA in HCC treatment, uc002mbe.2 
[57]. While lncRNAs are pivotal biological components in hepatocarcinogenesis, there is 
no doubt that their intensive study will give rise to more fruitful outcomes for HCC 
patients in the coming years. 
 
12 
 
4. Epigenetic regulation of lncRNAs in HCC 
Due to the abundance, diversity and complexity of lncRNAs, the dissection of their role 
in cancer pathogenesis is an active area of research. In this regard, how lncRNAs 
function at an epigenetic level has been much studied (recently reviewed in Mercer & 
Mattick 2013 [7]). LncRNAs are shown to be associated with more than 12 chromatin 
regulating proteins, targeting genes by methylation and acetylation [58]. LncRNAs that 
are epigenetically dysregulated in HCC are described in detail in the following section. 
Methylation 
The well characterised lncRNA, HOTAIR, adversely regulates multiple genes, in 
particular cell cycle regulators of hepatocarcinogenesis through its interaction with 
chromatin regulating proteins such as PRC2 and LSD1. This can lead to trimethylation 
and demethylation of H3K4, H3K27. Both HOTAIR and HEIH have been shown to 
enhance HCC progression by interacting with the essential component EZH2 in the 
PRC2 complex [59,41]. Moreover, the expression of MEG3 has been shown to be 
downregulated in HCC as a consequence of methylation in its promoter region. MEG3 
can be upregulated by methylation inhibitor 5-Aza-dc and microRNA29 via the inhibition 
of DNMT1 and DNMT3B [21]. 
Acetylation 
The downregulation of the tumour suppressor lncRNA LET under hypoxic conditions 
has been suggested to occur as a result of H3 and H4 deacetylation by HDAC3. This 
was shown to occur across the promoter region of LET and recovered to a normal level 
with the application of the HDACi TSA, even under hypoxia [47]. 
Methylation and acetylation 
While lncRNAs can regulate their target genes via epigenetic modifications in HCC, 
their aberrant expression has also been demonstrated to occur as a result of abnormal 
histone modifications (Figure 2). Specific locations within the HULC promoter region 
has been reported to be highly sensitive to acetylation (H3 and H4) and methylation 
(H3K4) [18].  The interaction between CREB and its binding site at the HULC promoter 
region was shown to be essential in HCC onset and progression. Furthermore, over-
expression of HULC may downregulate miR-372, the negative regulator of CREB. 
CREB is an essential player bridging Hbx with oncogenes such as HULC and yes-
associated protein (YEP) in the development of HBV-HCC [60]. While the 
overexpression of lncRNA H19 has been demonstrated in HCC, it was noted that H19 
may activate miR-200 family members including miR-200a, miR-200b, miR-200c, miR-
141 and miR-429 leading to subsequent suppression of genes involved in epithelial-
mesenchymal transition (EMT) such as zinc finger E-box binding homeobox 1/2 
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(ZEB1/2). This activation of miR-200 occurs as a result of an interaction between H19 
and the histone modification protein complex hnRNP U/PCAF/RNA PolII via the RNA 
binding member hnRNP U. This lncRNA-protein complex may elevate miR-200 family 
expression by increased H3 acetylation at the promoter region, causing a marked 
suppression in the metastatic potential of HCC [22]. In addition, the differentiated 
methylated region of the lncRNA H19 gene has been reported to be either hyper-
methylated or hypo-methylated in HCC [61]. 
Taken together, these results reveal an essential role for epigenetic regulation in 
upstream and downstream effects of lncRNA events that have been observed in the 
pathogenesis of HCC.  
 
In silico analysis of the lncRNAs and microRNAs intrinsic crosstalk in 
hepatotumorigenesis 
Bioinformatic resources have revealed that lncRNAs can interact with not only proteins, 
but also with RNAs, miRNAs and possibly DNAs [7]. It is noteworthy that several 
lncRNA database programs including NRED, lncRNAdb database and NONCODE v3.0 
have been generated to enable interrogation of the expression, sequences, functions 
and association of lncRNAs with other molecules. In addition, the newly founded 
LncRNADisease database can be used to predict diseases associated with lncRNAs 
and their neighbour genes [11]. We performed in silico analysis by using miRcode, a 
network that searches for potential target sites between miRNAs and lncRNAs in order 
to illustrate the potential influence of lncRNAs. The numbers of miRNAs associated with 
lncRNAs including H19, HOTAIR, MALAT1 and MEG3 are between 27 and 150, thus 
indicating a comprehensive association can occur between them. This computational 
analysis revealed that microRNAs (miR-130ac/301ab/301b/301b-3p/454/721/4295/3666) 
are associated with H19, HOTAIR and MEG3 at chromosome 11, 12 and 14 
respectively (Figure 3). Interestingly, miR-130b has been shown to be overexpressed in 
HCC cancer stem cells with the CD133 (+) marker [62]. Concomitantly, the miR-130 
family has been demonstrated to be upregulated under hypoxic conditions, this in turn 
elevates HIF-1α. These data indicate the importance of such miRNA-lncRNA 
interactions in hepatotumorigenesis (Figure 3). There is no doubt that when the 
miRcode database and other networks are expanded upon, further intrinsic linkages 
between lncRNA and microRNA will be revealed. These aspects will help in 
understanding the molecular mechanisms and influences that underscore HCC likely 
pointing towards better therapeutic strategies and diagnostic tools for this incurable 
disease. 
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6. Future challenges and opportunities 
LncRNAs are no longer considered backstage participants of biological processes. In 
fact, their discovery may represent a new era in the understanding of the pathogenesis 
of several disease states, in particular cancer [63]. Without doubt, the identification of 
new lncRNAs will continue in parallel with the development of modern scientific and 
computational technologies. While lncRNAs are abundant and diverse, to date the 
function of the vast majority of lncRNAs remains unclear. The impact that miRNAs are 
having in cancer biology is also vast. It has been suggested that there might be a well-
organised intrinsic network between lncRNAs and other ncRNAs such as miRNAs [20]. 
Investigation of such networks may lead to a clearer view of the complex molecular 
mechanisms in hepatocarcinogenesis and could lead to specific targeted therapies and 
diagnostics for HCC. Difficulty in early diagnosis and metastasis are central reasons 
that the mortality rate in HCC remains high. The abundance of lncRNAs suggest they 
may be ideal biomarkers for liver diseases associated with HCC (Table 3). On the other 
hand, the combination of using both lncRNAs and miRNAs will likely generate 
interesting avenues of basic and clinical research. Furthermore, there is strong 
evidence that the upregulation and downregulation of many lncRNAs are associated 
with HCC. Therefore, targeting these lncRNAs in combination with other therapeutic 
agents could have potential for HCC[64].  
 
 
7. Conclusions 
LncRNAs participate in most steps in genomic regulation from transcription, post-
transcription to chromatin regulation. While lncRNAs have gained increasing interest in 
recent years, their behaviour in HCC has led to an increased focus by many 
international leading laboratories. There is no doubt that the identification of novel 
lncRNAs and their investigation in HCC will continue at a rapid pace. 
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Figure legend 
Figure 1: Antisense regulation of lncRNA in HCC 
LncRNAs containing complementary sequences to target genes can act as antisense 
inhibiting their target genes including microRNAs and protein coding genes. For 
20 
 
example, lncRNA HULC may inhibit tumour suppressor genes such as micrRNA372 
and p18 in HCC. 
 
Figure 2: Epigenetic mechanism of lncRNA in HCC 
Histone modification of promoter regions in many lncRNA results in their aberrant 
expression; thus recruiting histone regulation proteins to modify the histone structure of 
their target genes. For example, interaction between phosphorylated CREB and CREB 
binding sites near the promoter region of the HULC gene upregulates the expression of 
HULC. Specific locations within the HULC promoter region are highly sensitive to 
acetylation (H3 and H4) and methylation (H3K4), this in turn makes HULC promoter 
region more susceptible to phosphorylated CREB from interaction. In addition, 
overexpression of dysregulated HULC inhibits CREB repressor miR-372, further 
exacerbating the onset and progression of HCC (especially in HBV-HCC).  
Figure 3: Computation analysis of lncRNA-microRNA interaction in HCC pathogenesis 
Utilising the miRcode program, a potential prediction between lncRNAs and microRNA 
in HCC pathogenesis has been postulated. The dysregulation of lncRNAs H19, HOTAIR 
and MEG3 may upregulate miR-130 family or vice versa, especially under hypoxic 
conditions in HCC tumours, in turn elevating HIF-1α and VEGF to facilitate the 
development of HCC. Meanwhile, overexpression of the miR-130 family in hepatocytes 
induces the formation of cancer stem cell, thus initiating hepatocarcinogenesis. 
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